Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Schuster

Showing results (491-500 of 630) with videos related to

Pageof 63
Sort By:
American Journal of Hematology|April 8, 2026
Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-UpJennifer A Woyach, Relja Popovic, Emily L Rossi, et al.
Blood Advances|July 24, 2019
Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusionMichael R Bishop, Richard T Maziarz, Edmund K Waller, et al.
Bone Marrow Transplantation|June 14, 2006
Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantationJ Svoboda, C Andreadis, R Elstrom, et al.
Journal of the American Chemical Society|July 21, 2021
A Design Strategy for Intrinsically Stretchable High-Performance Polymer Semiconductors: Incorporating Conjugated Rigid Fused-Rings with Bulky Side GroupsDeyu Liu, Jaewan Mun, Gan Chen, et al.
Transplantation and Cellular Therapy|May 21, 2023
Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T CellsDaniel J Landsburg, Sunita D Nasta, Jakub Svoboda, et al.
Blood Neoplasia|July 2, 2025
Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphomaNikita K Dave, Veronica Carvajal, Alex C Watts, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 5, 2015
Outpatient Autologous Stem Cell Transplantation for Patients With MyelomaThomas M Paul, Stephen V Liu, Elise A Chong, et al.
Blood|June 11, 2020
Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenomeQian Zhang, Elena J Orlando, Hong Y Wang, et al.
British Journal of Haematology|March 13, 2016
Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402Michael E Williams, Fangxin Hong, Randy D Gascoyne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402Brad S Kahl, Fangxin Hong, Michael E Williams, et al.
Pageof 63

Showing results (491-500 of 630) with videos related to

Sort By:
Pageof 63
American Journal of Hematology|April 8, 2026
Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-UpJennifer A Woyach, Relja Popovic, Emily L Rossi, et al.
Blood Advances|July 24, 2019
Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusionMichael R Bishop, Richard T Maziarz, Edmund K Waller, et al.
Bone Marrow Transplantation|June 14, 2006
Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantationJ Svoboda, C Andreadis, R Elstrom, et al.
Journal of the American Chemical Society|July 21, 2021
A Design Strategy for Intrinsically Stretchable High-Performance Polymer Semiconductors: Incorporating Conjugated Rigid Fused-Rings with Bulky Side GroupsDeyu Liu, Jaewan Mun, Gan Chen, et al.
Transplantation and Cellular Therapy|May 21, 2023
Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T CellsDaniel J Landsburg, Sunita D Nasta, Jakub Svoboda, et al.
Blood Neoplasia|July 2, 2025
Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphomaNikita K Dave, Veronica Carvajal, Alex C Watts, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 5, 2015
Outpatient Autologous Stem Cell Transplantation for Patients With MyelomaThomas M Paul, Stephen V Liu, Elise A Chong, et al.
Blood|June 11, 2020
Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenomeQian Zhang, Elena J Orlando, Hong Y Wang, et al.
British Journal of Haematology|March 13, 2016
Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402Michael E Williams, Fangxin Hong, Randy D Gascoyne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402Brad S Kahl, Fangxin Hong, Michael E Williams, et al.
Pageof 63